Get the Stockscreener App
38.40
7.20%
2.58
After Hours:
38.40
Springworks Therapeutics Inc stock is traded at $38.40, with a volume of 2.97M.
It is up +7.20% in the last 24 hours and up +0.55% over the past month.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
See More
Previous Close:
$35.82
Open:
$35.95
24h Volume:
2.97M
Relative Volume:
2.18
Market Cap:
$2.86B
Revenue:
-
Net Income/Loss:
$-275.16M
P/E Ratio:
-9.8715
EPS:
-3.89
Net Cash Flow:
$-221.15M
1W Performance:
+6.99%
1M Performance:
+0.55%
6M Performance:
+14.87%
1Y Performance:
-16.80%
1-Day Range:
$35.95
$40.12
1-Week Range:
$35.40
$40.12
52-Week Range:
$28.21
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Name
Springworks Therapeutics Inc
Sector
Industry
Phone
203-883-9490
Address
100 WASHINGTON BOULEVARD, STAMFORD, CT
Compare SWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
38.40 | 2.86B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Initiated | Evercore ISI | Outperform |
| Feb-05-24 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-04-19 | Initiated | H.C. Wainwright | Buy |
| Oct-08-19 | Initiated | Cowen | Outperform |
| Oct-08-19 | Initiated | Goldman | Buy |
| Oct-08-19 | Initiated | JP Morgan | Overweight |
| Oct-08-19 | Initiated | Wedbush | Outperform |
View All
Springworks Therapeutics Inc Stock (SWTX) Latest News
SpringWorks Therapeutics Inc (SWTX) Stock: A Look at the Monthly Trend - The News Heater
Analysts Expect Breakeven For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Before Long - Yahoo Finance UK
Can SpringWorks Therapeutics Inc (SWTX) meet market expectations this quarter? - US Post News
SpringWorks Therapeutics Breaks Above 200-Day Moving AverageBullish for SWTX - Nasdaq
Market Watch: SpringWorks Therapeutics Inc (SWTX)’s Noteworthy Drop, Closing at 35.82 - The Dwinnex
What Did We Note About Insider Trading At SpringWorks Therapeutics Inc (NASDAQ: SWTX)? - Stocks Register
FDA Action Alert: GSK, Indivior, SpringWorks, More - BioSpace
Four PDUFA dates on FDA’s February agenda - BioCentury
Vanguard Group Inc. Expands Holdings in SpringWorks Therapeutics Inc. - GuruFocus.com
SpringWorks Therapeutics to Report Fourth Quarter and Full - GlobeNewswire
SpringWorks Therapeutics Plans Major Q4 Update: Key Business Milestones & 2024 Performance Review - StockTitan
Learn to Evaluate (SWTX) using the Charts - Stock Traders Daily
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $70.00 Average PT from Analysts - Defense World
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 4.8%Here's What Happened - MarketBeat
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma - Marketscreener.com
AMI Asset Management Corp Takes $1.44 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Analysts Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Target Price at $70.00 - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6.4%Time to Sell? - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 4.3%Time to Buy? - MarketBeat
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
SpringWorks Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - MSN
Research Analysts Set Expectations for SWTX FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for SWTX FY2027 Earnings - Defense World
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap DownHere's What Happened - MarketBeat
Wedbush Research Analysts Reduce Earnings Estimates for SWTX - MarketBeat
JPMorgan Chase & Co. Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics’ SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Items Tagged with 'RPT-04402' - BioWorld Online
Items Tagged with 'SW-3431' - BioWorld Online
Springworks licenses molecular glue targeting PP2A from Rappta - BioWorld Online
Why Springworks Therapeutics Stock is Tumbling - TipRanks
SpringWorks Therapeutics (NASDAQ:SWTX) Given Outperform Rating at Wedbush - Defense World
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
Wedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
SpringWorks to Develop Rappta’s First-in-Class Cancer Drug - Contract Pharma
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
SpringWorks Therapeutics Reports Strong 2024 Financial Results - TipRanks
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
SpringWorks Therapeutics Reports Preliminary Fourth Quarter - GlobeNewswire
SpringWorks Therapeutics Hits $172M Revenue in 2024 as OGSIVEO Launch Accelerates Growth - StockTitan
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate (SWTX) - Seeking Alpha
SpringWorks Therapeutics jumps amid takeover speculation - MSN
Springworks Therapeutics Inc Stock (SWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):